Alphatec Holdings Inc. (NASDAQ:ATEC) is a top high short interest stock with significant potential. TD Cowen recently lowered its price target to $20 but maintained a Buy rating, citing the company’s growth vectors, like a 2026 revenue outlook of $890 million and exclusive US rights to Theradaptive’s OsteoAdapt bone graft.

Alphatec Holdings Inc. (NASDAQ:ATEC) partnered with Theradaptive to market OsteoAdapt, a revolutionary bone graft for spinal fusion. The collaboration aims to disrupt the $10 billion US spine biologics market by leveraging Alphatec’s commercial network to provide a regenerative solution that triggers natural bone growth.

Alphatec Holdings Inc. (NASDAQ:ATEC) is a medical technology company specializing in spinal disorder treatment. While ATEC shows promise, some AI stocks offer higher upside potential with less risk. For an undervalued AI stock that could benefit from current economic trends, check out Insider Monkey’s report on the best short-term AI stock.

Interested in stock market trends? Discover 30 stocks that could double in 3 years and 11 hidden AI stocks to buy right now on Insider Monkey. Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: TD Cowen Maintains Buy Rating for Alphatec (ATEC) While Adjusting PT to $20 Following Coverage Transfer